NucleoBio
NucleoBio is a privately held molecular diagnostics company developing Prostac™, a pre-FDA approved non-invasive blood test for early and precise prostate cancer detection. It serves men with elevated PSA scores, high-risk populations, and symptomatic patients via doctor's office blood draws.
- Company typePrivate
- Founded2016
- HeadquartersYonkers, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What NucleoBio does
NucleoBio, Inc. is a privately held molecular diagnostics company founded in 2016, headquartered in San Antonio, Texas. Its core product is Prostac™, a pre-FDA approved, non-invasive molecular-based blood test designed for the early and precise detection of prostate cancer. The test is intended to detect prostate cancer in men with elevated PSA scores, verify diagnoses in symptomatic men (blood in urine or semen, rapid weight loss, incontinence), screen for genetic predisposition in high-risk populations (men of African ancestry and those with family history), classify diagnosed cancers into risk groups ranging from indolent to aggressive castration-resistant, and monitor treatment effectiveness. According to preliminary data analysis on the company's website, Prostac™ is described as a better predictor of prostate cancer than PSA testing, with better specificity, sensitivity, and accuracy.
NucleoBio firmographics
Firmographics- Name
- NucleoBio
- Legal name
- NucleoBio, Inc.
- Website
- https://nucleobio.net
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NucleoBio is a privately held molecular diagnostics company developing Prostac™, a pre-FDA approved non-invasive blood test for early and precise prostate cancer detection. It serves men with elevated PSA scores, high-risk populations, and symptomatic patients via doctor's office blood draws.
- Ownership category
- akta.pro rank
NucleoBio industry classification
Industry- Product category
- Molecular Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Proteomics & Biomarker Analytical Testing (HLAGADAG), Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)
Keywords
Where NucleoBio is headquartered
LocationHeadquarters
- HQ city
- Yonkers
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NucleoBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Prostac™ Diagnostic Testing: Revenue from molecular diagnostic blood testing services for prostate cancer detection. The test is administered through doctors' offices and provides early detection, risk classification, and treatment effectiveness monitoring.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
NucleoBio product offering
Product offeringCore offering
NucleoBio develops and intends to commercialize Prostac™, a non-invasive, molecular-based blood test for the early and precise detection of prostate cancer. The test is intended to be drawn at a doctor's office and is designed to detect prostate cancer in men with elevated PSA scores or symptoms, screen for genetic predisposition, stratify diagnosed cancers by risk, and support physician treatment decisions and treatment effectiveness monitoring. Prostac™ is currently in pre-FDA approval stage.
Product overview
NucleoBio offers a single core product called Prostac™ — a molecular-based blood test for early, precise prostate cancer detection. The test is non-invasive, performed from blood drawn at a doctor's office, and is currently pre-FDA approved. Prostac™ serves multiple functions: detecting prostate cancer in men with elevated PSA scores or symptoms, screening for genetic predisposition (particularly for men of African ancestry and those with family history), classifying diagnosed cancers into risk groups, and assisting physicians in treatment decisions. Men testing negative may avoid expensive and intrusive follow-up procedures.
Differentiator
Problem solved
Functional benefit
Brands
- Prostac™: A molecular-based blood test for the early, precise detection of prostate cancer. Pre-FDA approved non-invasive screening test for men with elevated PSA scores or prostate cancer symptoms.
Products and services
- Prostac™ Molecular Blood Test A pre-FDA approved, non-invasive molecular-based blood test for the early and precise detection of prostate cancer. It is performed via blood draw at a doctor's office and is intended to detect prostate cancer in men with elevated PSA scores or symptoms, screen for genetic predisposition (notably men of African ancestry and those with a family history), classify diagnosed cancer into risk groups from indolent to aggressive castration-resistant, and assist physicians in treatment decisions and treatment effectiveness monitoring.
Quantifiable outcome
- Better predictor of prostate cancer than PSA with improved specificity, sensitivity, and accuracy (preliminary data)
Companies that use NucleoBio
Customer profileSegments4 records
Ideal customer profiles3 records
NucleoBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
NucleoBio partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights4 records
NucleoBio competitors and assessment
Company assessmentDirect peers
- Biodesix: Biodesix is a molecular diagnostics company focused on oncology, with blood-based assays for lung and other cancers. It is comparable to NucleoBio in its blood-based molecular diagnostic approach and physician-office distribution model.
- MDxHealth: MDxHealth commercializes SelectMDx and ConfirmMDx, both urine- and tissue-based molecular tests for prostate cancer detection and decision-making. It is the most directly comparable peer to NucleoBio's Prostac™ in clinical use case, customer (urologist), and blood/urine-based molecular assay modality.
- OPKO Health (4Kscore): OPKO Health's 4Kscore Test is a blood-based protein biomarker assay used to assess prostate cancer risk prior to biopsy. It competes head-to-head with Prostac™ for the same elevated-PSA patient population and physician channel.
- Bio-Techne (ExoDx Prostate IntelliScore): Bio-Techne markets ExoDx Prostate IntelliScore, a urine exosome-based molecular test that helps determine need for prostate biopsy. It is a direct competitor in the prostate cancer diagnostic reflex-testing market NucleoBio targets.
Broad incumbents
- Exact Sciences: Exact Sciences is a major molecular diagnostics company (Cologuard, Oncotype DX) with significant resources to enter or expand in prostate cancer. It is a broad incumbent in oncology molecular diagnostics and a likely strategic acquirer or competitor for NucleoBio.
- Philips (prostate cancer diagnostics): Philips offers multi-parametric MRI and image-guided biopsy solutions for prostate cancer detection. While more imaging-focused, it addresses the same diagnostic-decision pathway in urology practices where Prostac™ would be ordered.
- Hologic (Prolaris): Following its acquisition of Biotheranostics, Hologic offers the Prolaris molecular test for prostate cancer aggressiveness assessment. While a larger diversified diagnostics player, it competes with Prostac™ in risk stratification of diagnosed prostate cancer patients.
- Myriad Genetics: Myriad offers hereditary cancer and prostate cancer testing through its broader oncology diagnostics franchise. It is a broad incumbent competitor with established payor relationships relevant to Prostac™'s commercialization path.
Emerging players
- AnchorDx: AnchorDx is an emerging liquid biopsy company developing blood-based cancer detection tests. Its focus on blood-based molecular cancer diagnostics makes it a partial-overlap emerging peer to NucleoBio.
- Protean BioDiagnostics: Protean BioDiagnostics is an early-stage oncology diagnostics company developing biomarker-driven tests. As a smaller emerging player in cancer diagnostics, it is comparable to NucleoBio in scale, stage, and developmental focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
NucleoBio social profiles
Digital presenceNucleoBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
NucleoBio leadership team
Management profileNumber of profiles
Profiles2 records
NucleoBio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NucleoBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NucleoBio
What does NucleoBio do?
NucleoBio develops and intends to commercialize Prostac™, a non-invasive, molecular-based blood test for the early and precise detection of prostate cancer. The test is intended to be drawn at a doctor's office and is designed to detect prostate cancer in men with elevated PSA scores or symptoms, screen for genetic predisposition, stratify diagnosed cancers by risk, and support physician treatment decisions and treatment effectiveness monitoring. Prostac™ is currently in pre-FDA approval stage.
Is NucleoBio a public or private company?
NucleoBio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NucleoBio founded?
NucleoBio was founded in 2016. It employs 1 to 10 people.
Where is NucleoBio based?
NucleoBio is headquartered in Yonkers, United States, in the North America region.
How does NucleoBio make money?
One revenue line is on record: prostac™ Diagnostic Testing.
Who are NucleoBio's main competitors?
Direct peers on record are Biodesix, MDxHealth, OPKO Health (4Kscore) and Bio-Techne (ExoDx Prostate IntelliScore). Broad incumbents are Exact Sciences, Philips (prostate cancer diagnostics), Hologic (Prolaris) and Myriad Genetics. Emerging players are AnchorDx and Protean BioDiagnostics.
Does NucleoBio have an API?
No public API is recorded for NucleoBio.
What industry is NucleoBio in?
NucleoBio's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 621511 and its SIC code is 2835.